Silence Therapeutics plc

NASDAQ:SLN

Biotechnology

Healthcare
$19.80 +2.81%

+$0.19 today

Market cap
$935.23M
Beta
1.48
P/E (TTM)
-3.9
EPS (TTM)
-$1.80
52W Low $4.19High $8.40

Volume 1.21M

Average 0.31M

Returns on capital

Silence Therapeutics plc management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-142.2%

avg -142.2%

ROIC

-76.1%

avg -42.6%

ROA

-67.4%

avg -33.4%

Analysis

ROA is currently the strongest return metric at -67.4% versus its period average of -33.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Steven J. Romano

Executive Vice President and Chief Research & Development OfficerGBP 496.67K67300.00K0.64%

Rhonda L. Hellums

Executive VP, CFO, Secretary & Executive DirectorGBP 188.86K55——

Iain Gladstone Ross

Interim CEO & Chairman of the BoardGBP 131.26K72——

Marie Wikstrom Lindholm

Chief Scientific Officer————

Curtis Rambaran

Chief Medical Officer————

Jaimin Shah

SVP & General Counsel————

Gabriel

Chief Technical Operations Officer————

Gem Gokmen Hopkins

VP and Head of IR & Corporate Communications————

Marianna Anesti

VP & Head of Business Development————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jan 2, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

17

$104.14M

Sells

0

$0.00

Net Transaction Value

+$104.14M

Net buying

Most Active

Griffiths Richard Ian

17 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Aug 10, 26

Griffiths Richard Ian

Indirect

Buy$1.6M
Aug 10, 26

Griffiths Richard Ian

Indirect

Buy$44.7M
Aug 10, 26

Griffiths Richard Ian

Indirect

Buy$804.5K
Aug 10, 26

Griffiths Richard Ian

Indirect

Buy$57.2K
Aug 10, 26

Griffiths Richard Ian

Indirect

Buy$12.8M
Aug 10, 26

Griffiths Richard Ian

Indirect

Buy$6.1M
Aug 10, 26

Griffiths Richard Ian

Indirect

Buy$7.6M
Aug 10, 26

Griffiths Richard Ian

Indirect

Buy$9.7M
Aug 10, 26

Griffiths Richard Ian

Indirect

Buy$1.9M
Aug 10, 26

Griffiths Richard Ian

Indirect

Buy$981K

1–10 of 17

Summary

Insiders reported 17 buys worth $104.14M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $104.14M. Griffiths Richard Ian was the most active insider with 17 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/A-68.4%
+213.7% (5yr)3 analysts
Net IncomeN/AN/AN/A
N/A3 analysts
EBITN/AN/AN/A
N/A3 analysts

Analysis

Recent growth has been strongest in Revenue at -68.4% over three years. Forward estimates point to Revenue at +213.7% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Silence Therapeutics plc compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about SLN's management, answered from reported figures.

Who manages SLN?

Silence Therapeutics plc (SLN) lists 9 active executives. The top listed executive is Marie Wikstrom Lindholm, Chief Scientific Officer.

Are SLN insiders buying or selling?

Recent insider activity shows net buying of $124.31M.